Lumos Diagnostics Holdings Ltd. · ASX:LDX

Lumos Diagnostics — Corporate Update (October 2024)

9 slides from Lumos Diagnostics's corporate update, Oct 11, 2024

  1. Slide 1: Lumos and BARDA Partner to Support FebriDx

    For personal use only Investor Webinar Lumos and BARDA Partner to Support FebriDx 11 October 2024 lumosdiagnostics.com 1

  2. Slide 2: FebriDx - Bacterial / Non-Bacterial Point-of-Care Assay

    FebriDx - Bacterial / Non-Bacterial Point-of-Care Assay • A rapid POC test for acute respiratory infections For personal use only • Reliable differentiation of bacterial and non-bacterial etiology • 99% NPV to rule out bacterial Infections1 • Results after 10 minutes from a fingerstick • Easy-to-use

  3. Slide 3: FebriDx addresses a major need: Antibiotic Overprescription

    FebriDx addresses a major need: Antibiotic Overprescription ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE ANTIBIOTICS PRESCRIBED HOW WE’RE DRIVING MARKET ADOPTION For personal use only Common cold Marketing and education Sinusitis • Microbial testing prior to prescribing antibiotics not currently routi

  4. Slide 4: Market Opportunity in the US > $1Billion

    FebriDx Market Opportunity in the US > $1Billion MODERATE COMPLEXITY LIMITATION CLIA WAIVER EXPANDS ADDRESSABLE MARKET For personal use only Potential Customer Sites Potential Customer Sites 18,000 15x 270,000 Moderate Complex CLIA Waived • 18,0001 potential customer sites in US • 270,0002 potential

  5. Slide 5: BARDA – Promoting Advancement of Medical Countermeasures

    BARDA – Promoting Advancement of Medical Countermeasures For personal use only About BARDA (part of the U.S. Department of Health and Human Services) The Center for the Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of th

  6. Slide 6: CLIA Waiver Study

    FebriDx CLIA Waiver Study What is the study for…what is CLIA? • The Clinical Laboratory Improvement Amendment (CLIA) waiver study will demonstrate that the FebriDx test is simple to perform with a low risk of For personal use only erroneous results when performed by untrained users in expanded user

  7. Slide 7: Lumos and BARDA to Partner to Support FebriDx CLIA Waiver Study and Application

    Lumos and BARDA to Partner to Support FebriDx® bacterial/non-bacterial point-of-care test CLIA Waiver Study and Application Key highlights For personal use only • BARDA has awarded Lumos with US$2.984m in non-dilutive funding to support the CLIA waiver study and US FDA application o Payment over the

  8. Slide 8: Questions

    For personal use only Questions © Lumos Diagnostics 2020, all rights reserved Confidential 8 Confidential 8

  9. Slide 9: For personal use only

    For personal use only lumosdiagnostics.com 9

Lumos Diagnostics Holdings — Corporate Update (October 2024) on 6ix